Latest Regulatory Challenges News

Jameson Resources has cleared a key environmental hurdle for its Crown Mountain coal project in British Columbia, receiving a Section 27 Notice that sets the stage for final approvals. The company also raised A$3 million to fund the next phase of environmental assessment and Indigenous engagement.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

PYC Therapeutics has made significant progress across its four RNA therapeutic programs, including dose escalation approvals in its Polycystic Kidney Disease trial and orphan drug designation for its Retinitis Pigmentosa candidate, supported by a robust cash position of $669 million.

ALS Limited reported record FY26 financial results driven by strong growth in Minerals and Industrial Materials, while advancing its digital transformation through the Lab of the Future initiative. Leadership changes and a strategic portfolio review underpin its disciplined capital allocation approach.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.

The Star Entertainment Group reported a significant improvement in quarterly EBITDA loss alongside stable revenue, completing key joint venture exit and refinancing milestones that boosted liquidity to $267 million.

Macquarie Group reports a 30% profit increase in FY26 to A$4.85 billion as CEO Shemara Wikramanayake announces retirement, with Greg Ward set to take the helm in November 2026.

Vysarn Limited reported a record FY26 with NPBT of $20.9 million and operational revenue of $140.1 million, while completing the $50 million NewGround acquisition that boosts pro forma EPS by 26.7%.

Kingfish Limited outperformed the S&P/NZX50G with an 8.7% gross portfolio return in Q2 2026, driven by strong results from Fisher & Paykel Healthcare, Vista Group, and Infratil, while a2 Milk faced supply chain and regulatory challenges.

Richmond Vanadium Technology has appointed Seth McCann as General Manager for Development, Approvals & Studies, positioning the company to advance critical environmental and regulatory milestones for its Queensland vanadium project.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Mayfield Childcare has pulled its FY26 earnings guidance amid rising costs and regulatory shifts, while cautiously advancing its Mayfield 360 allied health initiative.